After having become became the first Indian Pharma company to receive WHO accreditation for anti-rabies vaccine, Cadila Healthcare Ltd today said it had received approval from the US Food & Drug Administration to market multiple doses of Risperidone tablets, the company said in a filing with the Bombay Stock Exchange.
Risperidone falls in the central nervous system (CNS) segment and is prescribed for the treatment of schizophrenia. The Risperidone tablets would be available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg doses.
The group has now 41 approvals and has so far filed 79 Abbreviated New Drug Application (ANDAs) since 2003-04.
Ahmedabad-based Zydus Cadila discovers, develops, manufactures and markets a broad range of healthcare products. The group's operations range from API to formulations, animal health products. The group has global operations in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.
Last week Zydus Cadila became the 1st Indian Pharma company to receive WHO accreditation for Rabies vaccine. '' WHO has approved Lyssavac N - the Purified Duck Embryo Rabies Vaccine (PDEV) manufactured by Zydus Cadila., for purchase by various United Nations Agencies (See: Zydus Cadila receives WHO prequalification accreditation for Rabies vaccine)